Tietoja työnantajasta
The Institute of Metabolic and Cardiovascular Diseases (I2MC) develops research to understand the pathophysiological mechanisms involved in common chronic non-communicable diseases: obesity, diabetes, thrombosis, atherosclerosis and diseases of the vessels, heart and kidney.
HISTORY
The Institute of Metabolic and Cardiovascular Diseases (I2MC) was created in 2011 from the merger of pre-existing research units located near the clinical services of the Toulouse Rangueil University Hospital. The I2MC has been renewed in 2021 for a 6-year term by Inserm and the University Toulouse III – Paul Sabatier (UMR 1297). The I2MC is composed of 11 research teams and 7 technological platforms for a total staff of 280 people. Scientists and clinicians work on metabolic risk factors (obesity, diabetes and dyslipidemia) and their cardiovascular complications (vascular diseases, thrombosis, atherosclerosis, heart and kidney failure). The I2MC has recognized expertise in cell biology, mouse models and clinical work supported by skills in lipidomics, genomics, proteomics, animal phenotyping and cellular imaging. The I2MC is at the center of a very active network of local, national and international collaborations. The I2MC offers opportunities to work on major chronic diseases in human health in the highly appreciated environment of Toulouse.
L’ORGANISATION DE L’I2MC
Research teams
Technological platforms
Administration and support services
Laboratory Council
SCIENTIFIC ADVISORY BOARD
An independent Strategic Scientific Committee (SAB), composed of experts in the Institute’s scientific fields, both French and foreign, is appointed by the Director of the I2MC. Its objective is to examine the Institute’s strategies, its organization and that of its teams in order to prepare and optimize each evaluation by the national supervisory authorities. The SAB advises the director and the team leaders in order to improve the organization of the Institute and its scientific production.